Jonathan Zippin
Dermatology · New York, NYNPI 1518126796
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,000 of the $21,952 with a category attached, or 72.9%. Pfizer accounts for 90.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $7,500 and has fallen 97.0% since, to $226 in 2024.
Across 10 payments — averaging $2195.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$20K
- Kowa Research Institute, Inc.$2K
- AbbVie$160
- Novartis$65
- LEO Pharma Inc.$26
Across 6 payments — averaging $43,939 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$238K
- Bristol Myers Squibb$26K
What the payments were for
- Consulting fees$5,68526%
- Speaking & faculty fees$16,00073%
- Food & beverage$2671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $19,950 |
| Kowa Research Institute, Inc. | 1 | $1,750 |
| AbbVie | 2 | $160 |
| Novartis | 1 | $65 |
| LEO Pharma Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,952 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 14 | $870 |
| Ketoconazole | 12 | $141 |
| Triamcinolone Acetonide | 14 | $98 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.